Macular degeneration usually refers to the age-related degenerative changes in the retina that can result in loss of central vision. It is caused by abnormal blood vessel growth (a condition ...

In response to the TGA's approval of a new drug to treat macular degeneration, UNSW researcher Dr Lisa Nivison-Smith provides context about the ...

Based on the scientific progress achieved in the past few years, it is possible that patients with myopic macular degeneration complicated by CNV may benefit from a new ophthalmic frontier of ...

Astellas Pharma Inc. (TSE: 4503) (President and CEO: Naoki Okamura, "Astellas") today announced the submission of a New Drug Application (NDA) to Japan's Ministry of Health, Labour and Welfare (MHLW) ...

Genome-wide association analyses identify distinct genetic architectures for age-related macular degeneration across ancestries. Nature Genetics , 2024; 56 (12): 2659 DOI: 10.1038/s41588-024-01764 ...

The Brooklyn-based startup is specifically targeting people with macular degeneration. The degenerative eye disease affects roughly 13% of U.S. residents aged 40 and up, according to figures from ...

Photodynamic therapy with verteporfin of CNV represents an advancement in the treatment of myopic macular degeneration complicated by CNV. The aim of PDT is to treat CNV, especially located into ...

SolidddVision smartglasses, the first true vision correction for people living with vision loss due to macular degeneration, is making its debut at CES 2025. Macular degeneration is an eye disease ...

Due to the relative rarity and low awareness surrounding MacTel type 2, diagnosis is often delayed, and the disease may be misdiagnosed, for example, as age-related macular degeneration (Charbel ...